Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Thymosin β4: a potential novel dry eye therapy.

Sosne G, Qiu P, Ousler GW 3rd, Dunn SP, Crockford D.

Ann N Y Acad Sci. 2012 Oct;1270:45-50. doi: 10.1111/j.1749-6632.2012.06682.x. Review.

PMID:
23050816
2.

Thymosin β4 significantly reduces the signs of dryness in a murine controlled adverse environment model of experimental dry eye.

Sosne G, Kim C, Kleinman HK.

Expert Opin Biol Ther. 2015;15 Suppl 1:S155-61. doi: 10.1517/14712598.2015.1019858. Epub 2015 Jun 22.

PMID:
26096547
3.

Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy, Dry Eye, and Ocular Surface Diseases.

Sosne G, Rimmer D, Kleinman HK, Ousler G.

Vitam Horm. 2016;102:277-306. doi: 10.1016/bs.vh.2016.04.012. Epub 2016 Jul 5. Review.

PMID:
27450739
4.

Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.

Sosne G, Dunn SP, Kim C.

Cornea. 2015 May;34(5):491-6. doi: 10.1097/ICO.0000000000000379.

PMID:
25826322
5.

Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4.

Dunn SP, Heidemann DG, Chow CY, Crockford D, Turjman N, Angel J, Allan CB, Sosne G.

Ann N Y Acad Sci. 2010 Apr;1194:199-206. doi: 10.1111/j.1749-6632.2010.05471.x. Review.

PMID:
20536469
6.

Primary Mechanisms of Thymosin β4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries.

Sosne G, Kleinman HK.

Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5110-7. doi: 10.1167/iovs.15-16890. Review.

PMID:
26241398
7.

Thymosin beta4 and corneal wound healing: visions of the future.

Sosne G, Qiu P, Kurpakus-Wheater M, Matthew H.

Ann N Y Acad Sci. 2010 Apr;1194:190-8. doi: 10.1111/j.1749-6632.2010.05472.x. Review.

PMID:
20536468
8.

Thymosin-beta4 modulates corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injury.

Sosne G, Christopherson PL, Barrett RP, Fridman R.

Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2388-95.

PMID:
15980226
9.

Progression of ocular sulfur mustard injury: development of a model system.

Milhorn D, Hamilton T, Nelson M, McNutt P.

Ann N Y Acad Sci. 2010 Apr;1194:72-80. doi: 10.1111/j.1749-6632.2010.05491.x. Review.

PMID:
20536452
10.

Towards a new in vitro model of dry eye: the Ex Vivo Eye Irritation Test.

Spöler F, Frentz M, Schrage NF.

Dev Ophthalmol. 2010;45:93-107. doi: 10.1159/000315023. Epub 2010 May 18.

PMID:
20502030
11.

Effects of eye drops containing a mixture of omega-3 essential fatty acids and hyaluronic acid on the ocular surface in desiccating stress-induced murine dry eye.

Li Z, Choi JH, Oh HJ, Park SH, Lee JB, Yoon KC.

Curr Eye Res. 2014 Sep;39(9):871-8. doi: 10.3109/02713683.2014.884595. Epub 2014 Feb 21.

PMID:
24559509
12.

Reversal of second-hand cigarette smoke-induced impairment of corneal wound healing by thymosin beta4 combined with anti-inflammatory agents.

Yuan H, Ma C, Moinet L, Sato N, Martins-Green M.

Invest Ophthalmol Vis Sci. 2010 May;51(5):2424-35. doi: 10.1167/iovs.09-3692. Epub 2009 Dec 17.

PMID:
20019366
13.

The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients.

Treadwell T, Kleinman HK, Crockford D, Hardy MA, Guarnera GT, Goldstein AL.

Ann N Y Acad Sci. 2012 Oct;1270:37-44. doi: 10.1111/j.1749-6632.2012.06717.x.

PMID:
23050815
14.

The use of angiogenic-antimicrobial agents in experimental wounds in animals: problems and solutions.

Suman P, Ramachandran H, Sahakian S, Gill KZ, Horst BA, Modak SM, Hardy MA.

Ann N Y Acad Sci. 2012 Oct;1270:28-36. doi: 10.1111/j.1749-6632.2012.06653.x.

PMID:
23050814
15.

Advances in the basic and clinical applications of thymosin β4.

Goldstein AL, Kleinman HK.

Expert Opin Biol Ther. 2015;15 Suppl 1:S139-45. doi: 10.1517/14712598.2015.1011617. Epub 2015 Jun 22. Review.

PMID:
26096726
16.

Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury.

Xiong Y, Mahmood A, Meng Y, Zhang Y, Zhang ZG, Morris DC, Chopp M.

Ann N Y Acad Sci. 2012 Oct;1270:51-8. doi: 10.1111/j.1749-6632.2012.06683.x.

17.

Corneal staining reductions observed after treatment with Systane Lubricant Eye Drops.

Christensen MT.

Adv Ther. 2008 Nov;25(11):1191-9. doi: 10.1007/s12325-008-0112-0.

PMID:
18972076
18.

Protection of thymosin beta-4 on corneal endothelial cells from UVB-induced apoptosis.

Ho JH, Su Y, Chen KH, Lee OK.

Chin J Physiol. 2010 Jun 30;53(3):190-5.

PMID:
21793328
19.

Combining Sodium Hyaluronate and Polyvinylpyrrolidone Therapies for the Rabbit Cornea: A New Approach to Relief of the Human Dry Eye Syndrome.

Ehrenberg M, Zolotariov E, Loeb E, Poliansky V, Levy A.

Curr Eye Res. 2015 Sep;40(9):913-22. doi: 10.3109/02713683.2014.969810. Epub 2014 Oct 20.

PMID:
25329624
20.

A novel dimeric thymosin beta 4 with enhanced activities accelerates the rate of wound healing.

Xu TJ, Wang Q, Ma XW, Zhang Z, Zhang W, Xue XC, Zhang C, Hao Q, Li WN, Zhang YQ, Li M.

Drug Des Devel Ther. 2013 Oct 1;7:1075-88. doi: 10.2147/DDDT.S50183. eCollection 2013.

Supplemental Content

Support Center